Business Wire

RMRK

Share
RMRK Raises $6m To Build Polkadot’s Advanced NFT System Standard

RMRK , an advanced NFT protocol project, announced today that it raised 6 million USD to build the standard cross-chain NFT infrastructure in the Polkadot and Kusama ecosystem. Investors such as D1 Ventures , YBB , PAKA , DFG , and others are all betting on NFTs 2.0 as presented by RMRK.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005768/en/

“NFTs right now are digital-dust-gathering assets, mainly overpriced digital pictures that you keep in your digital wallet until the next NFT hype wave hits.” says Bruno Škvorc, project founder and Web3 Foundation alum. “We believe that they’re meant for much more than that. NFTs can have long lasting liquidity by being upgradable, nestable within other NFTs, by being able to react to people reacting to them with emotes, and by being democratically governed through fractional ownership!”

By launching a gamified “initial collectible offering” called Kanaria on Kusama even without smart contracts, the RMRK team has pioneered the NFT-crowdfunding approach which netted them a total of 2 million USD in limited edition egg-nft sales. All egg buyers will also be entitled to a fairdrop of the coming $RMRK token. The remaining 4 million were raised directly from investors based on the vision of NFTs 2.0.

NFTs 2.0

RMRK is developing new standards to expand what NFTs can do:

● NFTs that can own other NFTs

● NFTs that can listen to commands or issue them to their children

● NFTs as DAOs that can, through fractional ownership, be controlled by a group

● NFTs that can react to emotion with conditional rendering logic (send 50 rocket emoji to a picture of a moon, and it can show you a moonbase)

● NFTs that can have multiple resources at once (mint an e-book with an audio version, a PDF file, and a high resolution cover - the environment it’s loaded in decides which part to load automatically).

With these “art legos” in place, RMRK has created an NFT operating system that makes possible NFT projects of arbitrary complexity .

Powerful Partnerships

This potential of art legos was recognized by key players in the Kusama and Polkadot ecosystem, as documented on RMRK’s official blog . Rather than crowd the already crowded parachain space, RMRK has opted to add their technology to other chains instead - the project’s very first runtime-based deployment will be with Unique Network , a dedicated NFT parachain project in the Kusama and Polkadot ecosystem.

With RMRK’s logic coming into the runtime functionality of several partner chains, the RMRK standards for NFTs 2.0 are poised to become the first shared-runtime environment in the Polkadot ecosystem, allowing for seamless teleportation of non fungible assets to and from any supported chain, natively, and at almost zero cost.

You can learn more about RMRK at rmrk.app , and you can play around with their official minting and trading UI for NFTs called Singular on singular.rmrk.app . Reach out to the team at hello@rmrk.app , on Telegram , or on Twitter , and read their blog on Subsocial .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release

Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio

SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release

Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye